Clinical Trial Update: A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating atezolizumab with obinutuzumab-based regimens in follicular lymphoma and diffuse large B-cell lymphoma has been completed with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Bendamustine (Bendamustine)
• CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)
• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Diffuse Large B-Cell Lymphoma, Lymphoma Follicular | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-06-13